Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 7, 2025BiomedicinesOpen Access

SGLT2 Inhibitors and GLP-1 Receptor Agonists in Cardiovascular–Kidney–Metabolic Syndrome

View Full Paper
Ask AI
Bookmark
Share

Authors

AGAryan GajjarARArvind Kumar Venkataramana RajuAGAmar Gajjar

Discussion

Loading...

Member takes

Overview

Review assesses the impact of SGLT2 inhibitors and GLP-1 receptor agonists on CKM syndrome, suggesting combination therapy may improve outcomes.

Key Points

  • MAIN FINDING: SGLT2 inhibitors and GLP-1 receptor agonists may significantly benefit individuals with CKM syndrome.
  • KEY EVIDENCE: Both therapies show positive effects on heart failure, glycemic control, and renal protection.
  • APPROACH: Review evaluates clinical evidence, mechanistic insights, and discusses combination therapy's potential advantages.
  • SIGNIFICANCE: Understanding these therapies can provide a patient-centered approach to managing CKM syndrome effectively.

Cite This Study

Gajjar et al. (2025) studied this question.

synapsesocial.com/papers/689dfe9fd61984b91e13c43dhttps://doi.org/10.3390/biomedicines13081924
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Established and Emerging Therapies for Cardiovascular-Kidney-Metabolic Syndrome: Harnessing the Benefits of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and Beyond2025
  2. 2Repurposing Diabetes Therapies in CKD: Mechanistic Insights, Clinical Outcomes and Safety of SGLT2i and GLP-1 RAs2025
  3. 3Managing glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in clinical practice2025
  4. 4Implementing SGLT2 Inhibitors in Cardiovascular–Kidney–Metabolic (CKM) Syndrome: A Multidisciplinary Expert Perspective2026
  5. 5Incretin-based therapies in diabetic kidney disease: toward integrated cardio-kidney-metabolic disease modification2026